PSTX - Poseida Therapeutics, Inc. Stock Price, Fair Value and News

$2.38-0.07 (-2.86%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

PSTX Price Action

Last 7 days

-2%

Last 30 days

-15.5%

Last 90 days

-30.6%

Trailing 12 Months

20.7%

PSTX RSI Chart

PSTX Valuation

Market Cap

237.9M

Price/Earnings (Trailing)

-2.11

Price/Sales (Trailing)

2.69

EV/EBITDA

-67.07

Price/Free Cashflow

1.1K

PSTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PSTX Fundamentals

PSTX Revenue

Revenue (TTM)

88.5M

Rev. Growth (Yr)

29.78%

Rev. Growth (Qtr)

-7.71%

PSTX Earnings

Earnings (TTM)

-112.8M

Earnings Growth (Yr)

-14.26%

Earnings Growth (Qtr)

-29.24%

PSTX Profitability

EBT Margin

-21.91%

Return on Equity

-185.43%

Return on Assets

-37.76%

Free Cashflow Yield

0.09%

PSTX Investor Care

Shares Dilution (1Y)

11.74%

Diluted EPS (TTM)

-1.17

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	82.5M	88.5M	0	0
2023	139.4M	156.7M	49.8M	64.7M
2022	56.1M	80.9M	105.7M	130.5M
2021	0	0	0	31.2M

Get all data in R, Python etc through our Historical Stock Data APIs

About Poseida Therapeutics, Inc.

Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC). It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers. In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma. Further, it is developing P-PSMA-101, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101, a liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; and P-PAH-101, a liver-directed gene therapy for the in vivo treatment of phenylketonuria. Poseida Therapeutics, Inc. has a research collaboration and license agreement with Takeda Pharmaceuticals USA, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.

CEO	Mr. Mark J. Gergen J.D.
WEBSITE	https://poseida.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	348

Poseida Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Poseida Therapeutics, Inc.? What does PSTX stand for in stocks?

PSTX is the stock ticker symbol of Poseida Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Poseida Therapeutics, Inc. (PSTX)?

As of Tue Oct 29 2024, market cap of Poseida Therapeutics, Inc. is 237.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PSTX stock?

You can check PSTX's fair value in chart for subscribers.

Is Poseida Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether PSTX is over valued or under valued. Whether Poseida Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Poseida Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSTX.

What is Poseida Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Oct 29 2024, PSTX's PE ratio (Price to Earnings) is -2.11 and Price to Sales (PS) ratio is 2.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSTX PE ratio will change depending on the future growth rate expectations of investors.